Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Mitsubishi Tanabe Pharma Development America, Inc.
EIR
•Mitsubishi Tanabe Pharma Development America, Inc.•October 15, 2021

Mitsubishi Tanabe Pharma Development America, Inc. – FDA EIR, Oct 15, 2021

Record Details

An FDA inspection of Mitsubishi Tanabe Pharma Development America, Inc., located in Jersey City, NJ, was conducted from October 12-15, 2021. This routine inspection assessed the firm's compliance with postmarketing adverse drug experience (PADE) reporting regulations, specifically reviewing pharmacovigilance activities for Exservan (NDA 212640) and Radicava (NDA 209176).

The inspection revealed two key issues. Firstly, the company's written procedures for reporting post-marketing adverse drug experiences lacked specific details regarding the required frequency and submission deadlines for periodic safety reports, including quarterly and annual reports, a deviation from 21 CFR 314.80(b). Secondly, the firm submitted two quarterly periodic adverse drug experience reports for Exservan late—three days and two days overdue, respectively. These delays stemmed from an incorrect calculation of reporting intervals, which the company had continued from the previous New Drug Application holder, violating 21 CFR 314.80(c)(2).

In response, management committed to reviewing and updating their written procedures to clearly define periodic safety reporting requirements and timelines. They also stated their plan to implement the correct reporting interval for all future periodic adverse drug experience reports to ensure timely submissions.

Company
Mitsubishi Tanabe Pharma Development America, Inc.
Inspection date
October 15, 2021
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Michael Serrano (investigator)
  • Tyanna N. Hadley (investigator)
View Company Profile

ID · 19ffbcc4-6b27-4aa3-b823-6f7e213b87c1

Violation Codes2
21 CFR 314.80(c)(2)21 CFR 314.80(b)

Full citation text and observation details available on the Dashboard.

Other documents for Mitsubishi Tanabe Pharma Development America, Inc.
  • 483 - 2021-10-15October 15, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Mitsubishi Tanabe Pharma Development America, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.